Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

Core Viewpoint - Lucid Diagnostics Inc. is set to host a business update conference call on March 24, 2025, to discuss its operations and financial results, highlighting its growth strategy in cancer prevention diagnostics [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [4]. - The company offers the EsoGuard® Esophageal DNA Test, which is the first and only commercially available tool aimed at early detection of esophageal precancer in at-risk patients [4]. Financial Update - During the upcoming conference call, the Chief Financial Officer will present the financial results for the fourth quarter of 2024, providing insights into the company's financial performance [1].